Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Radmila Kanceva"'
Autor:
Chris Wynne, Christian Schwabe, Emmanuelle Vincent, Armin Schueler, Janka Ryding, Martin Ullmann, Vishal Ghori, Radmila Kanceva, Michael Stahl
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 2, Pp n/a-n/a (2020)
Abstract MSB11455 is a proposed biosimilar to the currently licensed reference pegfilgrastim (Neulasta®). This study was designed primarily to compare the immunogenicity of MSB11455 and Neulasta®. As secondary objectives, the safety and tolerabilit
Externí odkaz:
https://doaj.org/article/7beea784365047a58e0ab0cad4fdf7c7
Publikováno v:
Rheumatology. 62
Background/Aims Macrophage activation syndrome (MAS), a form of secondary haemophagocytic lymphohistiocytosis, is a severe, life-threatening complication of rheumatic diseases such as Still’s disease (systemic juvenile idiopathic arthritis or adult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0fd2ae1661a75f425ef16c9bc5bbda0
https://doi.org/10.1093/rheumatology/kead104.131
https://doi.org/10.1093/rheumatology/kead104.131
Autor:
Armin Schueler, Michael Stahl, Christian Schwabe, Radmila Kanceva, Vishal Ghori, Janka Ryding, Chris Wynne, Emmanuelle Vincent, Martin Ullmann
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 2, Pp n/a-n/a (2020)
MSB11455 is a proposed biosimilar to the currently licensed reference pegfilgrastim (Neulasta®). This study was designed primarily to compare the immunogenicity of MSB11455 and Neulasta®. As secondary objectives, the safety and tolerability of MSB1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ddea1919d30b7b20327a9db012f413e
https://doaj.org/article/7beea784365047a58e0ab0cad4fdf7c7
https://doaj.org/article/7beea784365047a58e0ab0cad4fdf7c7
Autor:
Martin Ullmann, Michael Stahl, Corinne Seng Yue, Vishal Ghori, Paul M. Griffin, Jason D. Lickliter, Radmila Kanceva, Eleanor Harrison-Moench, Emmanuelle Vincent, Armin Schueler
Publikováno v:
Clinical therapeutics. 42(8)
Purpose MSB11455 is a proposed biosimilar to the reference pegfilgrastim (Neulasta®). This pivotal equivalence study (NCT03251248) assessed the pharmacokinetic and pharmacodynamic equivalence of MSB11455 to the reference product. Methods This 2-way,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::becec179a260790cc00d37346a09e1e4
https://pubmed.ncbi.nlm.nih.gov/32660769
https://pubmed.ncbi.nlm.nih.gov/32660769
Autor:
Chris, Wynne, Christian, Schwabe, Emmanuelle, Vincent, Armin, Schueler, Janka, Ryding, Martin, Ullmann, Vishal, Ghori, Radmila, Kanceva, Michael, Stahl
Publikováno v:
Pharmacology Research & Perspectives
MSB11455 is a proposed biosimilar to the currently licensed reference pegfilgrastim (Neulasta®). This study was designed primarily to compare the immunogenicity of MSB11455 and Neulasta®. As secondary objectives, the safety and tolerability of MSB1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8cf1601bda19e016c645476376404776
https://pubmed.ncbi.nlm.nih.gov/32333641
https://pubmed.ncbi.nlm.nih.gov/32333641
Autor:
James McKay, Pablo E. Pergola, Nelson Kopyt, Susanne Schmitt, Ajay K. Singh, Radmila Kanceva, Rajiv Agarwal, Jeffrey C. Fink, Gregor Schaffar, Matthew R. Weir, Anita Rudy, Jayant Kumar
Publikováno v:
American Journal of Nephrology. 46:364-370
Background: HX575 (biosimilar epoetin alfa) was approved in Europe in 2007 for the treatment of chronic kidney disease (CKD)-related anemia. This study assessed the clinical equivalence of HX575 with the US-licensed reference epoetin alfa (Epogen®/P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2bee29d074c45f7893a71b7a29d411f
https://doi.org/10.1159/000481736
https://doi.org/10.1159/000481736
Autor:
Michael Stahl, Armin Schüler, Paul M. Griffin, Pere Gascón, Emmanuelle Vincent, Jason D. Lickliter, Radmila Kanceva, Samer El Bawab, Eleanor Harrison-Moench
Publikováno v:
Journal of Clinical Oncology. 37:e14514-e14514
e14514 Background: MSB11455 is a proposed biosimilar to the currently licensed pegfilgrastim (Neulasta). This phase I study (NCT03251248) assessed the pharmacokinetic (PK)/pharmacodynamic (PD) bioequivalence of MSB11455 to Neulasta. Methods: Healthy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5963ae74eba028d1a9cd95fa0ee28070
https://doi.org/10.1200/jco.2019.37.15_suppl.e14514
https://doi.org/10.1200/jco.2019.37.15_suppl.e14514
Autor:
Lucie, Sosvorova, Radmila, Kanceva, Josef, Vcelak, Lyudmila, Kancheva, Milan, Mohapl, Luboslav, Starka, Eva, Havrdova
Publikováno v:
Neuro endocrinology letters. 36(6)
Cytokine production and immune activation are associated with various pathological conditions including neurodegenerative disorders. One of them is multiple sclerosis (MS), known autoimmune disease. Inflammatory changes were also reported in normal p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::141f77e1e534d8700a3d66a7a3dcc98b
https://pubmed.ncbi.nlm.nih.gov/26812299
https://pubmed.ncbi.nlm.nih.gov/26812299